Introduction
============

Septic arthritis of the hip joint may occur in adults with a debilitating disease or sepsis at other bodily sites, but the most common cause of a hip joint infection in the adult population is the incidence of a previous surgical procedure (such as an internal fixation of a fracture or the debridement of a lesion, excluding a hip arthroplasty) ([@b1-etm-0-0-7430]). This kind of disease is often persistent and recalcitrant. Due to the existence of articular cartilage damage and chronic osteomyelitis, the infection may transform into chronic septic arthritis ([@b2-etm-0-0-7430],[@b3-etm-0-0-7430]) and has a high debridement failure rate ([@b4-etm-0-0-7430]), which is difficult to cure and is a challenge for orthopedists.

A Girdlestone surgery involves the complete removal of a lesion via a head and neck incision, as well as a thorough debridement, which is more effective in treating chronic septic arthritis of the hip compared with the general debridement surgery ([@b5-etm-0-0-7430]). Subsequently, a complete hip arthroplasty can be performed following the infection is effectively controlled. However, patients usually appear with shortened extremities, arthralgia, and other symptoms after the two-stage surgery due to a soft tissue contracture, which seriously affects their quality of life ([@b6-etm-0-0-7430],[@b7-etm-0-0-7430]).

Usually, a surgical program including the removal of a prosthesis, a complete debridement, an implantation of an antibiotic cement spacer, and a subsequent total hip arthroplasty (THA) is effective for treating a periprosthetic joint infection (PJI) ([@b7-etm-0-0-7430]--[@b10-etm-0-0-7430]). Previous studies have adopted a similar staging surgical program (the incision of the head and neck combined with the implantation of a cement spacer) for treating refractory or chronic septic arthritides of the hip, which can maintain the length and function of the lower limbs and can prevent a muscle contracture prior to the stage II THA, thereby achieving excellent results ([@b1-etm-0-0-7430],[@b11-etm-0-0-7430]--[@b14-etm-0-0-7430]). Nevertheless, all of the previous studies focused only on the outcomes of using a bone cement spacer in patients receiving a staging hip arthroplasty but did not compare the outcomes in patients receiving a THA after the Girdlestone procedure alone. Thus, these studies did not obtain direct evidence that proved the advantages of the spacer method over the Girdlestone surgery.

The present study aims to explore the midterm (followed-up for at least 1 year) efficacy of a two-stage THA in treating chronic septic arthritis of the hip, as well as to compare the outcomes between patients who received and did not receive a cement spacer after the incision of the femoral head and neck.

Materials and methods
=====================

### Patient selection

Adult patients with chronic hip infections, who had each received a staging complete hip arthroplasty between January 2010 and January 2016 in the First Affiliated Hospital of Fujian Medical University, were retrospectively analyzed. These patients were initially diagnosed according to their disease history, clinical manifestations (local erythema, tenderness, exudation and pain) and imaging performances like disappearance of joint space and femoral head damage ([Fig. 1A](#f1-etm-0-0-7430){ref-type="fig"}). All patients underwent a preoperative joint cavity puncture, as well as an intraoperative joint fluid and tissue culture. The inclusion criteria were as follows: i) A chronic sinus connected to the joint cavity; ii) the presence of pus in the joint puncture or pus and destruction of femoral head during the surgery; iii) increased (\>20 mg/l) serum C-reactive protein (CRP) concentrations (detected using a Modular automated protein analyzer; IMMAGE800; Beckman Coulter, Inc., Brea, CA, USA) and positive frozen sections during the stage I surgery (numbers of white blood cells per high-power field \>5); and iv) cultures of the joint punctures or intraoperative specimens yielding positive results. A positive result was considered when at least one culture yielded a strict pathogen (*Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacteriaceae* and *anaerobes*) or when two cultures yielded a strain that was a skin commensal (including coagulase-negative staphylococci or *Propionibacterium acnes*) ([@b15-etm-0-0-7430]--[@b17-etm-0-0-7430]). The exclusion criteria were as follows: i) Patients with infections after a THA and ii) patients with incomplete clinical and laboratory information. Additionally, the following data of the patients were preoperatively collected: Cause of disease, causative organisms, comorbidities, CRP and erythrocyte sedimentation rate (ESR; detected using an Automatic ESR analyzer; Monitor-100; Vital, Puteaux, France).

### Surgical procedures

All surgeries were performed using the same approaches and procedures as described below and by the same experienced surgeon. The stage I surgery was performed as follows: An incision was made at the posterolateral region of the hip joint. The purulent fluid was sucked out and sent for bacterial culture and drug sensitivity examinations. Subsequently, the articular capsule was cut open to fully expose the hip joint (the internal fixture was taken out, if present) and was followed by the removal of the destroyed head and neck of the femur. Subsequently, the proximal femur was unreamed to prevent inflammation from the reaming to the medullary cavity. The purulent pus, inflammatory tissue, detached articular surface, and scar tissue were removed. For the Girdlestone alone group, the incision was closed after the drainage tube was placed ([Fig. 1B and C](#f1-etm-0-0-7430){ref-type="fig"}). For the cement spacer group, after debridement, 8 g vancomycin (Lilly, Indianapolis, IN, USA) was mixed with 80 g of bone cement (Refobacin; Zimmer Biomet, Warsaw, IN, USA), which was used to wrap two 4 mm Kirschner wire ([Fig. 2B](#f2-etm-0-0-7430){ref-type="fig"}) or cement prostheses ([Fig. 3](#f3-etm-0-0-7430){ref-type="fig"}) composed of a 28 mm femoral head, a 32 mm femoral neck and a 105 mm femoral stem (CM-CZ; AKMedical, Beijing, China) to make a spacer that matched the acetabular and femoral medullary cavities. The spacer was then implanted into the hip joint, which could help to maintain the normal eccentricity and tension of the gluteus medius. Finally, the incision was sutured after the drainage tube was fixed. After the surgery, the drainage tube was retained until a clear drainage fluid was observed and the drainage fluid volume was \>20 ml in both groups. The selection of antibiotics was based on the preoperative or intraoperative cultures and the drug sensitivity results, while vancomycin was applied in patients without culture results. The courses of intravenous and oral administration of antibiotics depended on the clinical symptoms as well as the CRP decline. After the patients received intravenous antibiotics ([Table II](#tII-etm-0-0-7430){ref-type="table"}) for 2--4 weeks, they were switched to oral antibiotics, which included 0.6 g levofloxacin (Daiichi Sankyo Co., Ltd., Tokyo, Japan) once per day and 0.3 g rifampicin (Chengdu Tiantaishan Pharmaceutical Co., Ltd., Chengdu, China) twice per day for 1--2 months. The affected limbs were allowed to gradually perform flexion and extension activities, as well as partial loading.

### Indications for stage II surgery

When movement of the hip did not incur obvious pain and the soft tissue did not appear to be swollen, patients underwent a CRP and ESR review a total of three times, with each review occurring once every week and yielding normal results. The stage II surgery was conducted using the original approach. The antibiotic bone cement spacer was removed, followed by an intra-articular scar clearance and debridement. The patients in both groups underwent THA using bioprosthesis (Johnson & Johnson Services, Inc., New Brunswick, NJ, USA).

### Evaluation indicators

Patients were assessed in terms of Harris hip scores ([@b18-etm-0-0-7430]) before the stage I surgery, between the two surgeries, and within the follow-up period (12.0--62.0 months; mean duration, 24.2±3.8 months) after the last surgery. The complications after the stage I surgery, the time of antibiotic applications after the stage I surgery, the interval between the stage I and stage II surgeries, the operation times, and the operative hemorrhage of the stage II surgery were recorded and the lengths of the lower extremities were postoperatively compared. In addition, the patients were reviewed using the inflammatory indicators (ESR and CRP) once every 3 months within the follow-up period, in order to monitor the recurrences of disease.

### Statistical analyses

All of the data are presented as the mean ± standard error of the mean. A Mann-Whitney U test was performed to evaluate the differences between the Girdlestone alone group and the Girdlestone + cement spacer group for all of the indicators analyzed. The statistical significance threshold was set at P=0.05.

Results
=======

### Analysis of included cases

According to the inclusion criteria, 16 patients were eligible for the present study. Among these patients, three patients with incomplete clinical data were excluded. Therefore, a total of 13 patients (14 hip joints, with one case of a bilateral infection) were enrolled in the study, including 8 men and 5 women, mean age 59.3±4.3 years; range 19--79 years. The present study included 7 cases (8 hip joints) of primary hip infections, 5 cases of infections after the internal fixation of the hip fracture (4 cases were femoral neck fractures and one case was an acetabular fracture), and one case of a chronic infection after the focal cleaning of osteonecrosis of the femoral head. All of the patients complained of symptoms for \>2 months ([Table I](#tI-etm-0-0-7430){ref-type="table"}). Ten patients had pain and swelling at the affected site, and two patients had pain symptoms and a sinus connected with the articular cavity. The symptoms of these patients lasted for 60--125 days (mean: 82.7±7.5 days) before the first surgery. Nine patients had a history of antibiotic use before the first surgery, while certain patients underwent incision drainages (cases 1, 3, 5, and 7) with no improvement in clinical manifestations ([Table I](#tI-etm-0-0-7430){ref-type="table"}). Beside the cases that were negative for the presence of bacterial cultures, half of the bacterial cultures of the two groups were comprised of gram-negative bacteria, which were different from the commonly found staphylococci and other positive cocci in PJI cases. On the basis of the bacterial culture results, the patients in both groups were given antibiotics, out of which two cases of negative cultures were given a combination of vancomycin and quinolones (levofloxacin; cases 7 and 10; [Table II](#tII-etm-0-0-7430){ref-type="table"}).

### Pathogen and stage I surgery

For the stage I surgery, 4 patients (5 hips) underwent the resection of the head and neck (cases 1--4, hereafter referred to as the Girdlestone alone group), and 9 patients (9 hips) underwent the resection of the head and neck combined with the implantation of a bone cement spacer (cases 5--13, hereafter referred to as the spacer group). In the Girdlestone alone group, the highly pathogenic *Burkholderia cepacia* was cultured in one case (case 1, [Fig. 1](#f1-etm-0-0-7430){ref-type="fig"}), which did not show significant complications after the stage I surgery but required a longer time duration for controlling the infection. One case had an incision sinus and infection recurrence after the surgery (case 3, *Escherichia coli*) and required a re-debridement and an extended anti-infective treatment. Another case had pneumonia, poor wound healing and other complications, and underwent a re-debridement (case 2, *Stenotrophomonas maltophilia*). The infection and complications in these three cases were under control and CRP levels were restored to a normal level after the stage I surgery in a mean of 8.4±1.5 weeks (range, 5--12 weeks). Among the patients undergoing a spacer implantation, two cases had complications. One case had a pneumonia and type I respiratory failure after the stage I surgery and was healed after treatment and underwent the stage II surgery successfully (case 6 with *Corynebacterium*). Another case had a spacer fracture after walking with weight loading at 3 months after the surgery and underwent the stage II surgery soon after (case 7). The mean time for CRP levels of the patients to decline to the normal level after the stage I surgery was 5.8±1.0 weeks (range 4--12 weeks), which was a shorter time period than that of the Girdlestone alone group. However, this difference was statistically insignificant. Additionally, two cases of the Girdlestone alone group who underwent a debridement after the stage I surgery suffered from poor wound healing again after the stage II surgery (cases 2 and 3) and were healed after receiving a debridement. However, all the patients in the spacer group were well healed. Signs of infection recurrence were not found in both groups until the end of the follow-up periods ([Table II](#tII-etm-0-0-7430){ref-type="table"}).

### Comparison of stage II surgery and postoperative implications in two groups

After the stage I surgery, the patients in the Girdlestone alone and spacer groups were given antibiotics for 120±3.2 weeks and 8.0±0.8 weeks, respectively, but this difference in antibiotic treatment times was statistically insignificant. The mean time interval between the two surgeries was 4.0±0.4 months in the spacer group, which was a significantly shorter time interval than that in the Girdlestone alone group (29.5±10.7 months, P\<0.01, [Table II](#tII-etm-0-0-7430){ref-type="table"}). The stage II arthroplasty was more difficult to perform in the Girdlestone alone group. The mean operation time was longer (124.0±13.6 vs. 105.6±7.9 min) and the incidence of a hemorrhage was increased more in the Girdlestone alone group (501.0±100.8 vs. 322.2±55.4 ml), but these differences were statistically insignificant. The Girdlestone alone group showed a more marked leg-length discrepancy after the stage II THA than the spacer group (2.8±0.6 vs. 0.8±0.2 cm, P\<0.01; [Table III](#tIII-etm-0-0-7430){ref-type="table"}).

All patients were followed up for \>12 months after the stage II surgery (12.0--62.0 months), with a mean of 24.2±3.8 months (Girdlestone alone group: 31.3±10.8 months; spacer group: 21.1±2.9 months). No cases had an infection recurrence or emerging infection surrounding the prosthesis, and no cases had prosthesis loosening, a dislocation, or a fracture around the prosthesis during the follow-up periods. The mean Harris scores before the surgery were comparable between the two groups (47.8±2.5 vs. 40.7±3.1; [Table IV](#tIV-etm-0-0-7430){ref-type="table"}). The Harris scores after the stage I replacement were 70.4±2.1 vs. 85.2±2.2 in the Girdlestone alone group and spacer group, respectively, which showed significant differences (P\<0.01). At the last follow-up, the Harris score in the spacer group was also improved than that in the Girdlestone alone group (81.6±1.1 vs. 88.9±1.7, P\<0.01; [Table IV](#tIV-etm-0-0-7430){ref-type="table"}).

Discussion
==========

The present study evaluated the midterm efficacy of a staged complete hip arthroplasty in treating the refractory septic arthritis of the hip. The comparison of the results from the follow-up in patients undergoing different surgical procedures showed that the application of an antibiotic cement spacer in addition to a head and neck resection could better control the infection. It could also maintain the limb length more effectively, thus providing more favorable conditions for the stage II complete hip arthroplasty, compared with the head and neck resection alone.

Previous literature has reported the unsatisfactory efficacy of a head and neck resection ([@b19-etm-0-0-7430]). It is generally believed that the joint is unstable, shortened, and often painful after the surgery. Additionally, it is not guaranteed that there is a complete and thorough debridement ([@b20-etm-0-0-7430],[@b21-etm-0-0-7430]). Rittmeister *et al* ([@b19-etm-0-0-7430]) reported 39 cases that underwent a head and neck resection of the hip joint and observed 67% incidence of complications and a repair rate of 44%. Charlton *et al* ([@b22-etm-0-0-7430]) found that the lower limb was shortened by an average of 30.5 mm after two resections of the head and neck; of these, 39 and 11.4% of the patients had a claudication and a dislocation after the stage II surgery, respectively.

The application of a spacer following a head and neck resection has been reported, wherein the spacer can be prefabricated or made by the surgeons during the surgery. Romanò *et al* ([@b13-etm-0-0-7430]) applied a prefabricated spacer made of gentamicin antibiotic loaded bone cement in 19 patients (20 hips). The authors found that hip arthroplasty was successfully implemented in all of the hips after a mean of 22 weeks, and only 1 case had infection recurrence during an average follow-up period of 56 months ([@b13-etm-0-0-7430]). Huang *et al* ([@b23-etm-0-0-7430]) used a variety of antibiotic bone cements to treat 14 cases (15 hips) with refractory septic hips and found an uncontrolled infection in only 1 case; no spacer-associated complications were observed. Among the 14 cases reported by Fleck *et al* ([@b12-etm-0-0-7430]), two died of other diseases, and two did not undergo the stage II surgery, while no case showed any sign of an infection recurrence. Shen *et al* ([@b14-etm-0-0-7430]) has questioned the traditional spacer method, they believed that an infection following hip trauma surgery was different from that of an infection following an arthroplasty. Since the infection might only involve the intra-articular soft tissue, cartilage, and subchondral bone, but not the proximal femur, the spacer with a femoral stem may lead to the involvement of the femoral medullary cavity and the spread of the infection. Thus, a spacer that does not need to be placed into the medullary cavity was used, and no infection recurrence and spacer associated complications were found during an average follow-up period of 39.6 months. Nonetheless, this kind of spacer could not achieve an axial and rotational stability that was similar to that of the traditional spacer; thus, this spacer had a higher risk of mechanical loosening and dislocation. Therefore, the conventional spacer was still adopted in the present study.

Two surgical methods were successfully used in the present study. It was found that, although the resection of the femoral head and neck could achieve a complete debridement, two patients had postoperative infection recurrences and poor wound healing, which greatly prolonged the time of antibiotic use and the interval between the two surgeries. The patients also suffered from shortened limbs and obvious dysfunctions, which may have led to great difficulties in the stage II hip arthroplasty. This may be because systemic medications did not help to achieve an effective concentration locally in patients with a poor blood supply, which led to a higher likelihood of an infection recurrence. Hsieh *et al* ([@b24-etm-0-0-7430]) used antibiotic beads locally after the Girdlestone surgery for treating a septic hip and achieved an improvement in the control of infection. For the implantation of an antibiotic bone cement spacer based on the stage I head and neck resection, a local release of antibiotics helped in controlling the infection and shortened the time of systemic application of the antibiotics. At the same time, the spacer was able to maintain the lengths and ranges of motion of the limbs ([@b25-etm-0-0-7430],[@b26-etm-0-0-7430]). It was not necessary to loosen the scar tissue during the stage II surgery, which resulted in a lower degree of operative hemorrhage and a shortened operation time. Additionally, the postoperative limbs were shortened by no more than 1 cm, the function was fully recovered, and no joint dislocation was reported during the follow-up. The spacer, which constructed using the bone cement prosthesis, is simple and inexpensive, has improved mechanical stability (compared with the Kirschner wire as the skeleton), and enables patients to walk with weight loading in an earlier time period following surgery, thus making it conducive for a functional recovery. This was therefore used instead of Kirschner wire in the later phase.

The selection of the implant in the stage II surgery is still controversial ([@b27-etm-0-0-7430]). Theoretically, the loss of bone mass in the septic hip is less than that in the infection following a THA, which is beneficial to the fixation of the biological prosthesis. A cementless bioprosthesis has been reported to have a good efficacy in treating an infection following a THA ([@b28-etm-0-0-7430],[@b29-etm-0-0-7430]). In addition, the use of a cement prosthesis has been reported to be insignificantly associated with an infection recurrence ([@b27-etm-0-0-7430],[@b30-etm-0-0-7430],[@b31-etm-0-0-7430]). Therefore, it is believed that a cementless prosthesis is a good choice for the stage II surgery for a septic hip. A bio-prosthesis was implemented in the stage II arthroplasty in most patients in this study. The results showed that the stability was immediately achieved during the surgery, no signs of loosening of the prosthesis were reported during the follow-up, and infections were well controlled in the patients. Other concerns in this study are the type and duration of antibiotic use. A systemic application of antibiotics is needed to not only control the primary foci but also prevent the hematogenous spread and infection metastasis. Despite reports that a short term application of intravenous antibiotics can also achieve the same effect as that of a long term application after spacer therapy for a refractory septic hip ([@b23-etm-0-0-7430],[@b32-etm-0-0-7430]), retrospective studies exist that only have a small number of cases and insufficient evidence. The bacterial cultures in this study revealed mostly gram-negative bacteria. Because of insufficient data showing the ideal doses and duration of antibiotic use, the patients were given intravenous antibiotics for at least 4 weeks after the stage I surgery, and the extended application was determined according to the changes in the inflammatory indicators.

The strengths of the present study were as follows: ([@b1-etm-0-0-7430]) All the patients received follow-ups; ([@b2-etm-0-0-7430]) all the surgical procedures were performed by the same surgeon in a standard manner; and ([@b3-etm-0-0-7430]) two surgical methods were compared. Since the patients were selected at different time-points, those patients receiving treatment after an improvement in the prosthesis and surgical techniques may show higher efficacy (a spacer was used in the late phase), which was the limitations of the present study. Nevertheless, this was unlikely to affect the credibility of the results as the use of the spacer significantly reduced the duration of antibiotic use, improved the function of the hip joints during the surgery, and maintained the lengths of the lower limbs. This, thereby simplified the stage II surgery, achieving improved final clinical efficacy. These effects showed a significant difference between the two groups. Evidently, this study included a small number of samples and hence further statistical analysis could not be performed. Furthermore, this was a retrospective study, in which patients were not randomly grouped and received follow-ups for a relatively short time. Therefore, further studies, with more patients and a long-term follow-up period are needed to provide more convincing comparative data. In conclusion, the present study found that a staging arthroplasty was conducive for a complete debridement in treating a chronic septic hip. The implantation of a bone cement spacer containing antibiotics in the stage I surgery could effectively control infection, avoid a joint contracture caused by a head and neck resection, reduce the risk of an infection recurrence between the two stages of the surgery. It could also effectively maintain the lengths of the lower limbs, simplify the stage II complete hip arthroplasty, and reduce an operative hemorrhage. Thus, it was a more effective method for treating a chronic septic hip arthritis.
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:   noninsulin-dependent diabetes mellitus

ORIF

:   open reduction internal fixation
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:   total hip arthroplasty

![Images of a patient receiving a femoral head and neck resection (case 1). (A) Male, 59 years old with bilateral hip joint pain and sinus present for 3 months, no improvement after receiving I&D and an antibiotic treatment. (B and C) The patient successively underwent resection of the head and neck of the left and right hips. Culture results revealed the presence of *Burkholderia pseudomallei*. After the surgery, the CRP did not decline to the normal level for a long period of time and the patient received prolonged course of antibiotics. (D) After 1 year the CRP returned to a normal level, the patient successively underwent a left and right total hip arthroplasty. During the operation it was found that soft tissue surrounding the hip joint was difficult to loosen; a large amount of scar hypertrophy and a severe operative hemorrhage were observed in the acetabulum. The postoperative bilateral lower limbs were shortened, and the hip joints had poor range of motion. CRP, C-reactive protein; I&D, incision and debridement.](etm-17-05-4123-g00){#f1-etm-0-0-7430}

![Images of a patient undergoing a femoral head and neck resection and spacer treatment (Case 5): (A) Male, 62 years old, pain for 3 months after the surgical treatment of a left acetabulum fracture, with purulence found in I&D and no improvement observed after receiving antibiotics. (B) The patient underwent a head and neck resection and an implantation of a bone cement spacer after the internal fixation was removed. (C) The infection was controlled after 3 months, and the patient underwent a hip arthroplasty, with a lower degree of operative hemorrhage. After the surgery, the lengths of the lower limbs were recovered and the hip joints had a good range of motion.](etm-17-05-4123-g01){#f2-etm-0-0-7430}

![A small cement prosthetic was used as a skeleton to fabricate a spacer (case 6). (A) A spacer mold and (B) a fabricated spacer using a cement prosthesis as the skeleton was implanted into the body.](etm-17-05-4123-g02){#f3-etm-0-0-7430}

###### 

Patient data (preoperative).

  Case   Age (years)/Sex   Cause of presentation   Duration of symptom (days)   Joint       Etiology                     Comorbidities                      Previous treatment for infection
  ------ ----------------- ----------------------- ---------------------------- ----------- ---------------------------- ---------------------------------- ----------------------------------
    1    59/M              Pain, sinus             L-60; R-35                   Bilateral   Primary                      Syphilis, osteoporosis             I&D, Cefradine
    2    54/M              Pain                    106                          Left        Primary                      Gout                               Aspiration
    3    61/M              Pain, sinus             120                          Right       Femoral neck fracture ORIF   Eczema                             I&D, Cefdinir
    4    67/M              Pain                    125                          Right       Primary                      NIDDM                              None
    5    62/M              Pain                      71                         Left        Acetabula fracture ORIF      Arterial hypertension, NIDDM       I&D, Moxifloxacin
    6    52/M              Sinus                     63                         Right       AVN focal cleaning           Cirrhosis                          Cefradine
    7    55/M              Pain, sinus               61                         Right       Femoral neck fracture ORIF   None                               I&D, Cefradine
    8    77/F              Pain                      64                         Right       Femoral neck fracture ORIF   Arterial hypertension, NIDDM, PD   Cefdinir
    9    49/F              Pain                    123                          Left        Primary                      None                               Cefradine
  10     75/F              Pain                    100                          Right       Primary                      None                               Cefradine
  11     79/F              Pain                      60                         Left        Primary                      None                               None
  12     62/M              Pain                      90                         Right       Primary                      NIDDM                              None
  13     19/F              Pain                      80                         Right       Femoral neck fracture ORIF   None                               Cefradine

AVN, Avascular necrosis; F, female; I&D, incision and debridement; M, male; NIDDM, non-insulin-dependent diabetes mellitus; L, left; R, right; ORIF, open reduction internal fixation.

###### 

Pathogen and stage I surgery.

  Case   Type of stage 1 surgery   Pathogen                       Antibiotics administration after stage 1 (IV)   Length of antibiotic therapy after stage 1 (weeks)   Interval to normal CRP (weeks)   Interval to THA (months)
  ------ ------------------------- ------------------------------ ----------------------------------------------- ---------------------------------------------------- -------------------------------- --------------------------
    1    Girdlestone               Burkholderia pseudomallei      Meropenem Ceftazidime                           L-24                                                 L-12                             L-12
                                                                                                                  R-10                                                 R-7                              R-9.5
    2    Girdlestone               Stenotrophomonas maltophilia   Meropenem                                       12                                                   12                               33
    3    Girdlestone               *Escherichia coli*             Levofloxacin                                      8                                                    6                              69
    4    Girdlestone               MRSA                           Vancomycin                                        6                                                    5                              24
    5    Spacer                    Enterobacter cloacae           Meropenem                                         6                                                    4                                3
    6    Spacer                    Corynebacterium                Vancomycin meropenem Cefoperazone                 8                                                    6                              5.5
    7    Spacer                    Negative                       Vancomycin moxifloxacin                           8                                                    4                              4.5
    8    Spacer                    Streptococcus                  Vancomycin levofloxacin                           8                                                    4                              3
    9    Spacer                    MSSA                           Vancomycin cefuroxime                             6                                                    4                              4
  10     Spacer                    Negative                       Vancomycin levofloxacin                         12                                                   12                               3
  11     Spacer                    MRSA                           Vancomycinlinezolid                             12                                                   10                               3
  12     Spacer                    MSSA                           Vancomycin                                        6                                                    3                              4
  13     Spacer                    MSSA                           Vancomycin                                        6                                                    5                              6

L, left; R, right; CRP, C-reactive protein; THA, total hip arthroplasty; MRSA, Methicillin-resistant Staphylococcus aureus; MSSA, Methicillin-susceptible Staphylococcus aureus.

###### 

Patient data (stage II surgery and postoperative implications).

  Case   Operative hemorrhage of THA (ml)   Duration of THA operation (min)   Leg-length discrepancy after THA (cm)   Preoperative hip score   Interim hip score   Final hip score   Complication between stages                   Complication after prosthesis implantation   Follow-up (months)
  ------ ---------------------------------- --------------------------------- --------------------------------------- ------------------------ ------------------- ----------------- --------------------------------------------- -------------------------------------------- --------------------
    1    L-200                              L-90                              L-2.0                                   L-54                     L-74                L-82                                                                                                         62
         R-400                              R-120                             R-2.2                                   R-52                     R-72                R-81                                                                                                         
    2    500                                150                               2.2                                     51                       75                  84                Pneumonia, hematosepsis, poor wound healing   Poor wound healing                           27
    3    600                                100                               5.0                                     49                       66                  83                Recurrence of infection, poor wound healing   Poor wound healing                           24
    4    805                                160                               3.0                                                              65                  78                                                                                                           12
    5    250                                90                                1.1                                     47                       85                  90                                                                                                           24
    6    600                                105                               2.0                                     48                       79                  89                Pneumonia, type-I respiratory failure                                                      28
    7    200                                70                                1.0                                     53                       85                  93                                                                                                           36
    8    300                                80                                0.8                                     30                       90                  91                Spacer fracture                                                                            30
    9    200                                147                               0.7                                     45                       91                  84                                                                                                           16
  10     150                                115                               0                                       35                       75                  78                                                                                                           17
  11     500                                116                               1                                       42                       79                  94                                                                                                           13
  12     500                                127                               0                                       20                       95                  93                                                                                                           14
  13     200                                100                               0.5                                     25                       88                  88                                                                                                           12

L, left; R, right; THA, total hip arthroplasty.

###### 

Comparison of the two surgical procedures.

  Surgical type          Operative hemorrhage of THA (ml)   Duration of THA operation (min)   Leg-length discrepancy after THA (cm)   Preoperative Harris hip score   Interim Harris hip score   Final Harris hip score
  ---------------------- ---------------------------------- --------------------------------- --------------------------------------- ------------------------------- -------------------------- ------------------------
  Girdlestone alone      501.0±100.8                        124.0±13.6                        2.8±0.6                                 47.8±2.5                        70.4±2.1                   81.6±1.1
  Girdlestone + spacer   322.2±55.4                         105.6±7.9                         0.8±0.2                                 40.7±3.1                        85.2±2.2                   88.9±1.7
  P-value                0.1658                             0.2812                            0.0015                                  0.1783                          0.0020                     0.0175

THA, total hip arthroplasty.

[^1]: Contributed equally
